18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

(2011) Eline Beert et al.   GENES CHROMOSOMES & CANCER

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign

(2009) Matthias R. Benz et al.   CANCER

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1

(2009) Victoria S. Warbey et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

POTENTIAL ROLE OF 18FLUORODEOXYGLUCOSE–POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN DIFFERENTIATING BENIGN NEUROFIBROMA FROM MALIGNANT PERIPHERAL NERVE SHEATH TUMOR ASSOCIATED WITH NEUROFIBROMATOSIS 1

(2009) Konstantina Karabatsou et al.   NEUROSURGERY

Combined PET/MRI: a new dimension in whole-body oncology imaging?

(2008) Gerald Antoch et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Malignant Peripheral Nerve Sheath Tumors

(2008) Gaurav Gupta et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study

(2007) R. E. Ferner et al.   ANNALS OF ONCOLOGY